论文部分内容阅读
为了明确卡莫司汀(BCNU)药动学与环磷酰胺一顺铂一卡莫司汀疗法之后的急性肺损伤之间是否有关联,作者研究了29例乳腺癌和9例非何杰金淋巴瘤患者,每例给予环磷酰胺1875mg/(m~2·d)(lh内静滴)共3天,顺铂55mg/(m~2·d)(72h内持续静滴),在顺铂输注完毕立即静滴卡莫司订600mg/m~2(2h内滴完).结果表明,38例中的20例(53%)在治疗后出现肺损伤.20例中的12例的卡莫司汀血药浓度一时间曲线下面积的值(AUC)上超过600(ug/mL)×min.而另18例中仅有2例(11%)超过此值却并未发生肺损
To determine if there is a correlation between carmustine (BCNU) pharmacokinetics and acute lung injury after cyclophosphamide-cisplatin-monocarmine therapy, the authors studied 29 breast cancers and 9 non-Hodgkin’s Lymphoma patients were given cyclophosphamide 1875mg / (m ~ 2 · d) (intravenous infusion within 1h) for 3 days, cisplatin 55mg / (m ~ 2 · d) (72h continuous intravenous infusion) Platinum infusion immediately after the infusion of carmustine set 600mg / m ~ 2 (2h drip end) .The results showed that in 38 cases, 20 cases (53%) after treatment, lung injury in 20 cases, 12 cases The area under the curve of carmustine concentration over time (AUC) exceeded 600 (ug / mL) x min, while only 2 of 11 (18%) exceeded this value without lung injury